TickerTain
$SPCX····$NVDA····$MSFT····$GOOGL····$ANTHROPIC·$TSLA····$CRWV····$NBIS····$HIMS····$TSM····$ASML····$FIGURE·$LYFT····$UBER····$SNOW····$META····$ELEVENLABS·$CURSOR·$COGNITION·$OPENAI·$AAPL····$RKLB····$XAI·$AMZN····$AMD····$000660.KS····$INTC····
← newsroom
Longevity & Aging · Hair loss treatment shifts from taboo to wellness category, mirroring GLP-1/obesity trajectory
now playing · Longevity & Aging
Healthcare Systems & Policytailwindscore 8/10pablo villalba
Medical device FDA pathway offers years-faster approval vs drugs, attracting strategic aesthetic partners
Classifying hair regrowth as a medical device rather than drug cuts regulatory timeline from 10+ years to months, enabling faster commercialization and attracting established aesthetic dist…
Medical Aesthetics Devicestailwindscore 7/10pablo villalba
Electromagnetic stimulation cap targets hair loss via NASA bone-healing tech with FDA device pathway
Low-frequency electromagnetic fields (100Hz) can reactivate viable hair follicles by leveraging cellular magnetic sensitivity, offering a non-pharmacological alternative to minoxidil/finast…
Longevity & Agingtailwindscore 6/10pablo villalba
Hair loss treatment shifts from taboo to wellness category, mirroring GLP-1/obesity trajectory
Hair loss is following the same destigmatization path as weight loss, moving from hidden shame to open wellness category; early clinical validation and physician endorsement (dermatologists…